News & Updates
Filter by Specialty:
Gas-filled on par with fluid-filled IGB for obesity treatment
Current Food and Drug Administration (FDA)-approved intragastric balloon (IGB) systems, the gas-filled IGB (Obalon) and the fluid-filled IGB (Orbera), demonstrate similar effectiveness for the treatment of obesity, as shown in a recent study.
Gas-filled on par with fluid-filled IGB for obesity treatment
28 Jun 2023
Novel genetic marker predicts CHD risk in Chinese patients with T2DM
Researchers from the Chinese University of Hong Kong (CUHK) have discovered PDE1A rs10171703 as a novel genetic marker for coronary heart disease (CHD) in Chinese patients with type 2 diabetes mellitus (T2DM), indicating its potential utility for predicting CHD risk in this patient population.
Novel genetic marker predicts CHD risk in Chinese patients with T2DM
27 Jun 2023
Debunking the myth: There is no ‘obesity paradox’, new data suggest
Using alternative anthropometric measurements, a post hoc analysis that used data from the PARADIGM-HF* trial debunked the BMI-related ‘obesity paradox’ in a large cohort of patients with chronic heart failure with reduced ejection fraction (HFrEF).
Debunking the myth: There is no ‘obesity paradox’, new data suggest
26 Jun 2023
SGLT2 inhibitors score big, this time in gout
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
